Scientific article
Open access

Activation of FGF receptors is a new mechanism by which strontium ranelate induces osteoblastic cell growth

Published inCellular physiology and biochemistry, vol. 27, no. 3-4, p. 243-250
Publication date2011

Strontium ranelate (SrRan) is an anti-osteoporotic treatment that reduces the risk of vertebral and hip fractures. Recent in vitro studies suggest that the effect of strontium ranelate on osteoblastic cell growth likely involves two processes including activation of the calcium sensing receptor (CaSR) and a yet undefined mechanism. In the present study, we investigated the CaSR-independent molecular mechanism by which SrRan stimulates osteoblast growth.

  • Animals
  • Bone Density Conservation Agents/pharmacology
  • Cell Proliferation/drug effects
  • Cells, Cultured
  • Membrane Proteins/genetics/metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinase 1/genetics/metabolism
  • Mitogen-Activated Protein Kinase 3/genetics/metabolism
  • Organometallic Compounds/pharmacology
  • Osteoblasts/cytology/drug effects/metabolism
  • Proto-Oncogene Proteins c-akt/genetics/metabolism
  • Receptors, Calcium-Sensing/agonists/metabolism
  • Receptors, Fibroblast Growth Factor/antagonists & inhibitors/metabolism
  • Signal Transduction
  • Thiophenes/pharmacology
  • P38 Mitogen-Activated Protein Kinases/genetics/metabolism
Citation (ISO format)
CAVERZASIO, Joseph, THOUVEREY, Cyril. Activation of FGF receptors is a new mechanism by which strontium ranelate induces osteoblastic cell growth. In: Cellular physiology and biochemistry, 2011, vol. 27, n° 3-4, p. 243–250. doi: 10.1159/000327950
Main files (1)
Article (Published version)
ISSN of the journal1015-8987

Technical informations

Creation10/18/2012 10:38:00 AM
First validation10/18/2012 10:38:00 AM
Update time03/14/2023 7:56:20 PM
Status update03/14/2023 7:56:20 PM
Last indexation08/29/2023 5:36:21 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack